Progranulin variants
AssigneeDenali Therapeutics Inc.
InventorsGerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L. Y. Low, Rachel Prorok, Ankita Srivastava
Life of this patent
Estimating the term…
Abstract
Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
Claims28
A progranulin variant comprising an amino acid sequence having at least 90% identity to SEQ ID NO:2 and an amino acid sequence defined by X1X2X3 at the positions corresponding to amino acid residues 574 to 576 of SEQ ID NO:2, wherein X1X2X3 is selected from the group consisting of:
- PIL, PFL, PPL, PYL, QRL, and QHL.
An Fc fusion polypeptide comprising a progranulin variant and an Fc polypeptide, wherein the progranulin variant comprises an amino acid sequence having at least 90% identity to SEQ ID NO:2 and an amino acid sequence defined by X1X2X3 at the positions corresponding to amino acid residues 574 to 576 of SEQ ID NO:2, wherein X1X2X3 is selected from the group consisting of:
- PIL, PFL, PPL, PYL, QRL, and QHL.
Dependencies are inferred from the claim text.